Qualification of an IFN-γ ELISpot Assay for Monitoring Antigen-Specific T-Cell Responses in Clinical Trials of T-cell-inducing Vaccines
Year: 2026
Type: preprint
Abstract: The IFN-γ ELISpot assay is a sensitive, widely used platform for quantifying antigen-specific T-cell responses and serves as a benchmark assay for immunomonitoring in vaccine trials. Despite its broad adoption, clinical use requires formal qualification to ensure reproducibility, reliability, and fitness for use. However, standardised, qualified ELISpot assays remain scarce for clinical trials in Africa. We present an IFN-γ ELISpot assay for measuring antigen-specific T-cell responses in human PBMCs qualified under Good Clinical Laboratory Practice (GCLP) standards. Assay performance was evaluated using predefined parameters, including linearity, precision, specificity, detection capacity, robustness, and reportable range, across multiple PBMC stimulation conditions. Linearity was assessed across six different cell inputs per well using the CEFSX stimulation. Precision was assessed via the predefined coefficient of variation (CV) threshold of ≤ 35% across the evaluated stimulation conditions. Robustness was assessed using a one-factor-at-a-time approach across different post-thawing and incubation times for the three stimulations. Strong linearity was observed across the donor samples (R2=0.90-0.98). All samples met the precision acceptance criteria across all tested conditions, demonstrating performance consistent with accepted standards in the field. Intermediate precision was similarly robust, with minimal operator-dependent variability and 94.4% of replicate values falling within the predefined acceptance limits. There was no significant effect of different post-thawing and incubation times on the assay output (p-value >0.05), and the assay achieved 100% specificity. Overall, the qualified assay demonstrated strong analytical performance and readiness for immunomonitoring in clinical vaccine trials. Importantly, this work establishes our lab as a GCLP-certified African site for clinical vaccine trial immunomonitoring of IFN-γ ELISpot assays.
Source: Research Square
Authors: Tiza Ng’uni(Methodology, Project administration, Resources, Supervision, Visualization, Writing – review & editing), Alabi W. Banjoko(Data curation, Formal analysis, Methodology, Resources, Software, Visualization, Writing – original draft, Writing – review & editing), Nitalia Naidoo, Lorraine Tshegofatso Maebele(Investigation, Methodology, Writing – review & editing), Mali Mlaba(Investigation), Namani Ngema(Investigation), Crystal A. Mendoza(Writing – review & editing), Zaza M. Ndhlovu(Conceptualization, Funding acquisition, Resources, Supervision, Validation, Writing – review & editing)
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
Awards: Africa Health Research Institute NPC - to expand access to spatial imaging capabilities in Africa for infectious disease research, Africa Health Research Institute NPC - to characterize the full spectrum of transcription program of immune cells that modulate the HIV reservoir, Africa Health Research Institute NPC - to expand the scope of tissue immunology research in Africa through supporting the placement and training of spatial -omics technology that can be ...
OpenAlex ID: W7234046669
